
|Articles|November 13, 2009
Diabetes & Obesity Podcasts: Obesity Drugs and Co-Morbidities
Advertisement
Diabetes & Obesity Series
Obesity Drugs and Co-Morbidities
Subscribe to RSS feed of this series
Dr. Richard Gregg
Chief Scientific Officer
Vitae Pharmaceuticals
Dr. Gregg offers insight into the development of obesity drugs, and how co-morbidities factor into development, as well as how it impacts sites and CROs in Phase I through III trials.
Others in the Series
Diabetes Resources
- Articles, Multimedia
Diabetes Drugs in Development, 2009
Associations and Societies
Clinical Trials
Obesity Resources
Articles, Multimedia
Associations and Societies
Clinical Trials
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters
2
ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap
3
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
4
ACT Brief: Funding Gaps and Indication Decisions in Early-Stage Programs, Recruitment Funnel Leak Diagnosis, and Mega-Merger Speculation Denial
5




